does fda antidepressant labeling recommend screening for bipolar disorder with a questionnaire?
“They recommend screening for bipolar disorder with a tool like the mood disorder questionnaire before starting any antidepressant.”
a host, a psychiatrist said on The Carlat Psychiatry Podcast, 2026-11-16, at 20:09. hear it in context → the speaker cited: the FDA's labeling.
the episode: Kraepelin on Clancy Part 3 (at 20:09). we link the show's own page; we do not re-host audio.
first, the part that holds
this part is right: FDA labeling for antidepressants does tell prescribers to screen for bipolar disorder before starting treatment. Current labels word it as screening for a personal or family history of bipolar disorder, mania or hypomania before starting "this drug or another antidepressant", and older-format labels carry the same instruction.
what we found when we went and looked
we read antidepressant labels through openFDA, the FDA's public label database: a current escitalopram label, an older-format sertraline label and a dextromethorphan-bupropion label. All three tell prescribers to screen for bipolar disorder before starting an antidepressant, so that part of the claim holds. None of them names the mood disorder questionnaire or any other screening tool. The current labels ask for a personal and family history of bipolar disorder, mania or hypomania. The older sertraline label says the screening "should include a detailed psychiatric history", including family history of suicide, bipolar disorder and depression. A full-text openFDA search for "mood disorder questionnaire" came back with no match. The questionnaire is a clinical tool, not something FDA labeling recommends.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| FDA antidepressant labeling recommends screening for bipolar disorder before starting an antidepressant | confirmed | the current escitalopram label (section 2.4) says that before starting escitalopram or another antidepressant, prescribers should screen for a personal or family history of bipolar disorder, mania or hypomania. The dextromethorphan-bupropion label has the same instruction in section 2.1 and repeats it in warning 5.4. The older-format sertraline label has a warning headed 'screening patients for bipolar disorder'. We read three labels, not every antidepressant label. [1][2][3] |
| the screening instruction applies before starting any antidepressant | confirmed | this is class-wide labeling. The escitalopram label says 'escitalopram or another antidepressant'. The same kind of instruction appears in labels for an SSRI and for a non-SSRI combination product. We sampled labels rather than checking every antidepressant, so this rests on the class-labeling wording plus our sample. [1][2][3] |
| FDA labeling recommends a tool such as the mood disorder questionnaire for this screening | misattributed | none of the three labels we read names a questionnaire, scale or formal instrument. The current labels ask about personal and family history. The older sertraline label calls for 'a detailed psychiatric history', including family history of suicide, bipolar disorder and depression. An openFDA full-text search of all indexed labels for 'mood disorder questionnaire' returned no match (HTTP 404, which is how openFDA reports an empty result; we did not see the response body). The tool comes from clinical practice and is being credited to the FDA. [1][2][3] |
both directions
for the speaker: the core of the claim is on the label. FDA class labeling for antidepressants tells prescribers to screen for bipolar disorder, mania or hypomania before starting this drug or another antidepressant. The reason given is that treating a depressive episode with an antidepressant alone in someone with bipolar disorder can bring on a mixed or manic episode. The speaker's phrase "a tool like" can be heard as an example of how to screen rather than a quote from the label, and using a validated questionnaire is one reasonable way to carry out an instruction that doesn't specify a method.
against: the speaker named the FDA's labeling as the source. On the method, the labeling says something different from the claim: it asks for a personal and family history and, in older wording, "a detailed psychiatric history". It does not mention the mood disorder questionnaire or any other instrument. Listeners could come away thinking a questionnaire is an FDA expectation before every antidepressant prescription. It isn't. The label sets the goal (screen for bipolar risk) and, where it says anything about method, points to history-taking.
what this cannot say
we read three labels in full-text form through openFDA, not all of the hundreds of antidepressant labels. The negative search for "mood disorder questionnaire" depends on openFDA's index, and we saw a 404 status rather than the response body. Old-format labels without the newer section 2 wording may phrase the instruction differently. FDA safety communications and professional guidelines are separate from labeling and were not the subject of this check. We have only the quote, not the full context of the episode, so we can't tell whether the speaker presented the questionnaire as the label's wording or as their own suggestion.
the medication pages behind this check
sources, each one fetched and read
- U.S. Food and Drug Administration, openFDA drug label API, escitalopram prescribing information (record last updated 2026-11-13) What we read there: section 2.4: 'prior to initiating treatment with escitalopram or another antidepressant, screen patients' for a personal or family history of bipolar disorder, mania or hypomania. Section 5.5: activation of mania/hypomania occurred in 1 of 715 (0.1%) escitalopram-treated patients in placebo-controlled MDD trials. No screening instrument is named. Fetched 2026-11-16 (HTTP 200). https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22escitalopram%22+AND+_exists_:boxed_warning&limit=1
- U.S. Food and Drug Administration, openFDA drug label API, sertraline hydrochloride prescribing information (older label format) What we read there: a warning headed 'screening patients for bipolar disorder' says patients with depressive symptoms 'should be adequately screened to determine if they are at risk for bipolar disorder' and that 'such screening should include a detailed psychiatric history', including family history of suicide, bipolar disorder and depression. No questionnaire is named. Fetched 2026-11-16 (HTTP 200). https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22sertraline%22+AND+openfda.product_type:%22HUMAN+PRESCRIPTION+DRUG%22&limit=1
- U.S. Food and Drug Administration, openFDA drug label API, dextromethorphan-bupropion prescribing information What we read there: section 2.1: 'screen patients for a personal or family history of bipolar disorder, mania, or hypomania'. Warning 5.4: prior to initiating, screen patients for a history of bipolar disorder. No instrument is named. Fetched 2026-11-16 (HTTP 200). https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22bupropion%22+AND+dosage_and_administration:%22bipolar%22&limit=1
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam